HC Wainwright Brokers Decrease Earnings Estimates for SYRS

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Syros Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($2.79) per share for the year, down from their prior estimate of ($2.13). HC Wainwright currently has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.94) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.25) EPS.

Several other research analysts have also weighed in on the company. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock opened at $0.20 on Monday. Syros Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a market cap of $5.33 million, a PE ratio of -0.09 and a beta of 1.59. The firm’s 50 day moving average price is $1.99 and its two-hundred day moving average price is $3.73.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the firm earned ($1.35) earnings per share.

Insider Buying and Selling

In other Syros Pharmaceuticals news, CEO Conley Chee purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. The trade was a 222.18 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jason Haas acquired 45,344 shares of the stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the transaction, the chief financial officer now owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This trade represents a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 130,707 shares of company stock valued at $206,491 over the last ninety days. 12.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in Syros Pharmaceuticals in the first quarter valued at approximately $64,000. GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals during the third quarter valued at about $34,000. Acadian Asset Management LLC purchased a new stake in Syros Pharmaceuticals during the 1st quarter valued at about $91,000. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $109,000. Finally, Vanguard Group Inc. grew its holdings in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares during the last quarter. 91.47% of the stock is owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.